Medicine, Health & Food

Medicine, Health & Food


Pages: 10  ,  Volume: 45  ,  Issue: 1 , January   2020
Received: 20 Jan 2020  ,  Published: 15 March 2020
Views: 82  ,  Download: 0


# Author Name
1 fajriani
2 Joko S Lukito
3 Delyuzar



Background: Background: MUC1 has become a topic of concern in cancer treatment because of its upregulation which might influence the invasion, proliferation, and survival of tumor cells by reducing cell adhesion and extracellular cell-matrix adhesion. Besides, stray overexpression from MUC1 is associated with angiogenesis and chemoresistance in cancer. Thus MUC1 has a role in tumorigenesis, progressive and metastasis, this can function as an underlying prognostic factor. An accurate biomarker for early diagnosis and a more accurate prognosis can improve the efficiency of current treatment in breast cancer and is a molecular marker for target therapy.

Objective: To evaluate the MUC1 immunohistochemistry characteristics and expression in invasive breast carcinoma.

Materials and Methods: A descriptive study with a cross-sectional approach, using tissue paraffin blocks from 42 patients with invasive breast carcinoma and given a MUC1 immunohistochemistry appearance, then a broad percentage of MUC1 expression was assessed.

Results: MUC1 immunohistochemistry expression in invasive breast carcinoma was mostly positive (76.2%). Based on the involvement of MUC1 immunohistochemistry expression based on the presence or absence of distant invasive breast carcinoma found in M1 the highest shows positive MUC1 expression (100%). Immunohistochemistry expression of MUC1 based on histopathological grading was obtained at the highest grade 3 showing positive MUC1 expression (93.8%). Immunoreactivity patterns of MUC1 expression found the most diffuse cytoplasmic patterns (26.2%).

Conclusion: The presence of distant metastases tends to show high positive MUC1 expression and there is also a tendency that if a histopathological grading is high then it will show that MUC1 expression is also highly expressed

Keywords: invasive breast carcinoma, MUC1 immunohistochemistry  expression, distant metastasis, histopathological grading


  • Invasive breast carcinoma
  • MUC1 immunohistochemistry expression
  • distant metastasis
  • histopathological grading
  • References

    1. Colditz G, Chia KS, Wilson R, Britton P, Morrow M, Rutgers E, et al. Invasive breast carcinoma: introduction and general features. In: Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, Vijver MJ, editors. WHO classification of tumours of the breast. Lyon: IARC; 2012. pp14-23.
    2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68. pp394-424.
    3. WHO. Breast cancer. IARC; 2018. Available from:  [Accessed 9th April 2019].
    4. WHO. Globocan 2018 latest global cancer data. IARC; 2018. Available from: [Accessed 9th April 2019].
    5. WHO. Asia. IARC; 2018. Available from: [Accessed 9th April 2019].
    6. WHO. Indonesia. IARC; 2018. Available from: [Accessed 9th April 2019].
    7. Kementerian Kesehatan RI. Bulan peduli kanker payudara. Jakarta: Pusat Data dan Informasi; 2016.
    8. Kementerian Kesehatan RI. Situasi penyakit kanker. Jakarta: Pusat Data dan Informasi; 2015.
    9. Lingga FH. Karakteristik penderita kanker payudara rawat inap di Rumah Sakit Haji Medan tahun 2014-2015. Medan: Universitas Sumatera Utara; 2016. Available from:  [Accessed 25th June 2019].
    10. Banurekhaa B. Prevalensi kanker payudara pada wanita di RSUP H. Adam Malik pada tahun 2009. Medan: Universitas Sumatera Utara; 2011.  Available from: [Accessed 25th June 2019].
    11. Taha MNA. Prevalensi dan karakteristik penderita kanker payudara di Departemen Bedah RSUP H. Adam Malik Medan tahun 2010. Medan: Universitas Sumatera Utara; 2012. Available from: [Accessed 25th June 2019].
    12. Fandini I. Karekteristik penderita kanker payudara di RSUP H. Adam Malik tahun 2016. Medan: Universitas Sumatera Utara; 2017. Available from: [Accessed 25th June 2019].
    13. Lester SC. The breast. In: Kumar V, Abbas AK, Aster JC, editors. Robbin and cotran pathologic basis of disease. 9th Edition. Philadelphia: Saunders; 2015. pp1051-67.
    14. Gannon LM, Cotter MB, Quinn CM. The classification invasive carcinoma of the breast. Expert Rev Anticancer Ther. 2013;13(8). pp941-54.
    15. Hanafi-Bojd MY, Moosavian Kalat SA, Taghdisi SM, Ansari L, Abnous K, Malaekeh-Nikouei B. MUC1 aptamer-conjugated mesoporous silica nanoparticles effectively target breast cancer cells. Drug Dev Ind Pharm. 2018;44. pp13-8.
    16. Merikhian P, Ghadirian R, Farahmand L, Mansouri S, Majidzadeh AK. MUC1 induces tamoxifen resistance in estrogen receptor-positive breast cancer. Expert Rev Anticancer Ther. 2017;17. pp607-13.
    17. Goode G, Gunda V, Chaika NV, Purohit V, Yu F, Singh PK. MUC1 facilitates metabolic reprogramming in triple-negative breast cancer. PloS One. 2017.
    18. Zhou D, Xu L, Huang W, Tonn T. Epitopes of MUC1 tandem repeats in cancer as revealed by antibody crystallography: Toward glycopeptide signature-guided therapy. Molecules. 2018.
    19. Kufe DW. MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches. Oncogen. 2013;32. pp1073-81.
    20. Sung-Im D, Kyungeun K, Dong-Hoon K, Seoung WC, Yong LP, Chan HP, Association between the expression of Mucins (MUC1, MUC2, MUC5AC, and MUC6) and clinicopathologic parameters of human breast ductal carcinomas. J Breast Cancer. 2013 June; 16(2). pp152-8.
    21. Patel DS, Khandeparkar SGS, Joshi AR, Kulkarni MM, Dhande B, Lengare P. Immunohistochemistry  study of MUC1, MUC2 and MUC5AC expression in primary breast carcinoma. Journal of Clinical and Diagnostic Research. 2017;11(4). pp30-4.
    22. Do SI, Kim K, Kim DH, Chae SW, Park YL, Park CH, et al. Associations between the expression of mucins (MUC1, MUC2, MUC5AC, and MUC6) and clinicopathologic parameters of human breast ductal carcinomas. Journal of Breast Cancer. 2013;16(2). pp152-8.
    23. Elseed SMH, Abdelaziz MS, Salih NS, Elnaeem MM, El-fatih M, Mudawi AI. Mucin 1 (MUC1) over expression and intracellular localization pattern in invasive ductal breast cancer using immunohistochemistry. American Journal of Research Communication. 2015;3. pp119-28.
    24. Baldus SE, Wienand JR, Werner JP, Landsberg S, Drebber U, Hanisch FG, et al. Expression of MUC1, MUC2 and oligosaccharide epitopes in breast cancer: prognostic significance of a sialylated MUC1 epitope. International Journal of Oncology; 2005. pp1289-97.
    25. Radecka B and Litwiniuk M. Breast cancer in young women: review. Ginecology Polska. 2016;87. pp659-63.
    26. Gabriel AC and Domchek SM. Breast cancer in young women: review. Breast Cancer Research; 2010.
    27. Peters ITA, Hilders CGJM, Sier CFM, Vahmeijer AL, Smit VTHB, Trimbos JB, et al. Identification of cell-surface markers for detecting breast cancer cells in ovarian tissue. Arch Gynecol Obstet. 2016;294. pp385-93.
    28. Garbar C, Mascaux C, Cure H, Bensussan A. MUC1/CD227 immunohistochemistry in routine practice is a useful biomarker in breast cancers. Journal of Immunoassay and Immunochemistry. 2013;34. pp232-45.
    29. Van der Vegt B, de Roos MAJ, Peterse JL, Patriarca C, Hilkens J, de Bock GH, et al. The expression pattern of MUC1 (EMA) is related to tumour characteristic and clinical outcome of invasive ductal breast carcinoma. Histopathology. 2007;51. pp322-35.
    30. Tang Y, Cui X, Xiao H, Qi S, Hu X, Yu Q, et al. Binding of circulating anti-MUC1 antibody and serum MUC1 antigen in stage IV breast cancer. Molecular Medicine Reports. 2017;15. pp2659-64.
    31. Metastatic breast cancer: overview; 2012 Available from: [Accessed 14th December 2019].
    32. Jin X and Mu P. Targeting breast cancer metastasis. Breast Cancer: Basic and Clinical Research. 2015;9. pp23–34.
    33. Ellis IO, Collins L, Ichihara S, MacGrogan G. Invasive carcinoma of no special type. In: Lakhani SR, Ellis IO, Schnitt SJ, Tan HP, Vijver MJ, editors. WHO classification of tumors of the breast, 4th edition; Lyon: IARC; 2012. pp34-8.
    34. Rakha EA, Filho JSR, Baehner F, Dabbs DJ, Decker T, Eusebi V, et al. Breast cancer prognostic classification in the molecular era: the role of histological grade: review. Breast Cancer Research; 2010.
    35. Wu G, Kim D, Kim JN, Park S, Maharjan S, Koh H, et al. A mucin1 C-terminal subunit-directed monoclonal antibody targets overexpressed mucin1 in breast cancer. Research Paper. Theranostics. 2018;8(1). pp78-91.
    36. Rakha EA, Boyce RWG, El-Rehim DA, Kurien T, Green AR, Paish EC, et al. Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancer. Modern Pathology. 2005;18. pp1295-1304.
    37. Wang YW, Shi DB, Liu YM, Sun YL, Chen X, Xiang S, et al. Abberant expression of CD227 is correlated with tumor characteristic and invasiveness of breast carcinoma. J Cancer Res Clin Oncol; 2014.
    38. Lau SK, Weiss LM, Chu PG. Differential expression of MUC1, MUC2, and MUC5AC in carcinomas of various sites. Am J Clin Pathol. 2004;122. pp61-9.
    39. Jing X, Liang H, Hao C, Yang X, Cui X. Overexpression of MUC1 predict poor prognosis in patients with breast cancer. Oncology Reports. 2019;41. pp 801-10.
    40. Horm TM, Schroeder JA. MUC1 and metastatic cancer. Expression, function and therapeutic targeting. Cell Adh Migr. 2013;7(2). pp187-98.